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Abstract. The activity of CB1 cannabinoid receptors was studied in postmortem brain samples of Alzheimer’s disease (AD)
patients during clinical deterioration. CB1 activity was higher at earlier AD stages in limited hippocampal areas and internal
layers of frontal cortex, but a decrease was observed at the advanced stages. The pattern of modification appears to indicate
initial hyperactivity of the endocannabinoid system in brain areas that lack classical histopathological markers at earlier stages
of AD, indicating an attempt to compensate for the initial synaptic impairment, which is then surpassed by disease progression.
These results suggest that initial CB1 stimulation might have therapeutic relevance.
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INTRODUCTION
The decline in synaptic function appears at early
stages of Alzheimer’s disease (AD), which correlates
with cognitive dysfunction in AD patients [1, 2] at
areas innervated by the cholinergic cells of the basal
forebrain [3, 4]. The neuropathological markers, used
for the classification of AD patients in different stages,
have been found in subjects without dementia that may
represent a preclinical stage of the illness [5].
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The study of the endocannabinoid synapse is
particularly interesting with regard to AD because
cannabinoid receptor expression and other components
of the endocannabinoid system have been found to
be modified [6]. Reduction of CB1 receptor density
has been described in the hippocampus and caudate-
putamen [7]. The localization of the cannabinoid
receptors in the brain suggests its involvement in
the modulation of learning and memory [8]. Some
cannabinoid compounds are able to induce amnesia
and memory deficits in mice [9] and regulate fear-
conditioned memory [10]. In addition, increase in
cannabinoid tone appears to induce neuronal survival
[11]. The genetic deletion of CB1 receptors induces
neuronal loss in the hippocampus, accompanied by
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a decline in cognitive functions [12]. Therefore, the
activity mediated by CB1 receptors might regulate
some cognitive functions and neuroprotective actions.
In the present study, we analyze the activity and den-
sity of CB1 cannabinoid receptors in postmortem tissue
from patients during AD progression.
MATERIALS AND METHODS
Brain tissue samples from 17 control cases and 36
AD patients were obtained from the tissue bank of the
Hospital of Bellvitge, Barcelona. The AD patients were
divided into three groups according to Braak’s stages
[13, 14], and were matched for age, postmortem delay,
and freezing storage time.
Tissue sections were incubated with 0.04 nM
guanosine [35S]5′-O-[gamma-thio]triphosphate
([35S]GTPS). Agonist-stimulated binding was
measured in the presence of the specific cannabinoid
receptor agonist WIN55,212-2 (10−4 M), and consec-
utive slices were incubated with 3 nM [3H]CP55,940
(more details in Supplementary Material).
Differences between groups of patients were
analyzed using the Kruskal-Wallis non-parametric
test followed by Dunn’s post-hoc test. Correlations
were applied to compare the [35S]GTPS with the
[3H]CP55,940 binding sites (Pearson’s or Spearman’s
test).
RESULTS
In the present study, we used functional [35S]GTPS
autoradiography to analyze the frontal cortex (Brod-
mann area 8), amygdala, basal forebrain (nucleus
basalis of Meynert, nbM), striatum, hippocampus,
and entorhinal cortex for CB1-mediated activation of
Gi/o proteins in the presence of the cannabinoid ago-
nist WIN55,212-2. We also employed [3H]CP55,940
autoradiography to calculate the density of CB1 recep-
tors.
Analysis of the [35S]GTPS binding stimulated by
WIN55,212-2 (Table 1) showed an upward trend dur-
ing AD stages I-II of the functional CB1 receptors at
layer VI of frontal cortex.
The activity of CB1 receptors was lower during AD
stages V-VI than during stages I-II in the pyramidal
and radiatum layers of the hippocampal CA1. The
increased activity measured in the AD I-II group com-
pared with the control group was partially responsible
for this significant effect. This increase was statis-
tically significant in the hilus of the dentate gyrus
during stages I-II and decreased during stages V-VI.
At stages III-IV, the CB1 activity was similar to the
control group in most of the hippocampal areas (Sup-
plementary Fig. 1). The increased activity at stages I-II
might be delaying the deterioration of CB1-mediated
activity. In contrast, in the lateral nucleus of the amyg-
dala, CB1-mediated activity decreased from the initial
stages of the disease. In the nbM and striatal areas, CB1
activity was not altered in AD.
We quantified the cannabinoid receptor density by
measuring the specific labeling of the radioligand
[3H]CP55,940 (Table 2). The CB1 cannabinoid recep-
tors were upregulated in layer VI of the frontal cortex
in patients with stage III-IV AD. In the hippocam-
pus, CB1 receptor density was altered in different
hippocampal subfields in AD patients depending on
the AD stage. Receptor density was increased relative
to control cases mainly during AD stages III-IV. The
density of receptors decreased to or fell below con-
trol levels at the most advanced stages (Supplementary
Fig. 1). In the amygdala, CB1 density was very low,
and the measured densities of cannabinoid receptors
were maintained during disease progression. Cannabi-
noid receptor density was not altered in the nbM of
AD patients. In the caudate-putamen, the CB1 receptor
density increased during the initial stages of AD com-
pared with control densities and a trend to decrease to
control levels was observed during the next stages.
DISCUSSION
The aim of the present study was to analyze the
status of the endocannabinoid system during AD
progression. Patients were divided in three groups
according to Braak’s neuropathological stages (stages
I-II, III-IV, and V-VI) [13, 15]. We observed regu-
lation of the activation of the signaling cascade by
Gi/o proteins mediated through cannabinoid recep-
tors during AD progression. The data obtained from
the [3H]CP55,940 autoradiography did not correlate
with the WIN55,212-2-stimulated binding. Therefore,
receptor density and receptor efficiency are modulated
separately. The different lipid composition of the neu-
ronal membranes can modulate the CB1 activity [16].
The frontal cortex tissue sections from AD patients
exhibit an apparent increase of the CB1 activity in
the AD I-II stages compared to AD III-IV. Previous
studies that analyzed CB1 receptor density and expres-
sion in cortical areas did not describe changes in AD
[7, 17], but other binding and PET studies showed
that CB1 densities were reduced in frontal cortex [6,
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Table 1
Autoradiographic densities for the specific binding of [35S]GTPS in human brain (nCi/g t.e.) stimulated by WIN55,212-2 in frontal cortex,
hippocampus, and entorhinal cortex of control and AD patients
Brain area Control AD I-II AD III-IV AD V-VI
Frontal cortex (n = 4) (n = 5–8) (n = 6)
Layer I-III 45 ± 33 64 ± 23 53 ± 23 –
Layer IV 20 ± 15 71 ± 26 53 ± 33 –
Layer V 59 ± 55 130 ± 49 82 ± 47 –
Layer VI 78 ± 68 212 ± 430 125 ± 60 –
Hippocampus (n = 4–7) (n = 3–5) (n = 3–4) (n = 4–8)
CA1
Lacunosum moleculare 101 ± 34 238 ± 76 29 ± 37 129 ± 17
Oriens 134 ± 58 197 ± 43 – 100 ± 56
Pyramidal 296 ± 82 512 ± 109 – 194 ± 25∗,d
Radiatum 166 ± 31 321 ± 70 – 154 ± 33∗,d
CA3
Lacunosum moleculare 176 ± 113 484 ± 120 323 ± 152 140 ± 19
Oriens 147 ± 39 227 ± 65 – 91 ± 34
Pyramidal 252 ± 88 436 ± 156 – 162 ± 31
Radiatum 218 ± 53 451 ± 122 – 93 ± 37
Dentate gyrus
Granular 80 ± 23 201 ± 75 27 ± 33 0 ± 6∗,d
Hilus 87 ± 22 236 ± 83∗,a 15 ± 29 11 ± 6∗,d
Molecular 258 ± 61 523 ± 142 171 ± 62 80 ± 32∗,d
Subiculum
Lacunosum moleculare 110 ± 42 208 ± 72 42 ± 40 90 ± 36
Oriens 101 ± 54 219 ± 32 64 ± 28 73 ± 25
Pyramidal 301 ± 44 525 ± 123 205 ± 69 152 ± 36∗,c,d
Radiatum 236 ± 89 324 ± 162 111 ± 56 138 ± 49
Entorhinal cortex (n = 4–7) (n = 3–5) (n = 3–4) (n = 4–8)
Layer I 165 ± 35 417 ± 239 116 ± 109 108 ± 56
Layer II-III 218 ± 55 364 ± 226 175 ± 136 105 ± 29
Layer IV-VI 169 ± 45 407 ± 203 173 ± 107 88 ± 35
Amygdala (n = 4) (n = 8–12) (n = 7–9)
Lateral nucleus 321 ± 159 −68 ± 51∗,a 58 ± 88∗,b –
Basal nucleus (magnocellular) 44 ± 46 90 ± 32 55 ± 15 –
Basal forebrain (n = 7) (n = 12) (n = 9) (n = 5)
Nucleus basalis (Meynert) 138 ± 38 173 ± 66 97 ± 55 113 ± 64
Striatum (n = 6) (n = 13) (n = 11) (n = 9)
Caudate-putamen 277 ± 97 197 ± 48 170 ± 45 169 ± 50
Data are mean ± SEM values. (n): number of cases used. (–): less than three samples available. The p values were calculated by the Kruskal-
Wallis non-parametric test followed by Dunn’s test. aAD I-II versus control, bAD III-IV versus control, cAD V-VI versus control, dAD I-II
versus AD V-VI. ∗p < 0.05.
18, 19]. The increase of CB1 receptor activity that
we observed during the initial stages of AD might
indicate a neuroprotective action mediated by endo-
cannabinoids in response to initial neural damage,
which has been extensively reviewed [20]. Analysis
of the [3H]CP55,940 binding sites during disease pro-
gression revealed a significant increase of CB1 receptor
density at layer VI of the frontal cortex in the AD
III-IV patient group. The results indicate that the regu-
lation of CB1-mediated activity precedes the increase
in receptor density. The increased efficiency could be
less metabolically costly to the cell than the increased
availability of new receptors.
Recent studies have reported a reduction in the
enzyme responsible for the synthesis of anandamide
in the cortex of AD patients [21]. The regulation of
the CB1 density and activity that we describe at cortex
might be a compensatory mechanism to balance the
anandamide signaling.
In a previous study CB1 receptor density has been
found decreased at the hippocampus in AD patients
[7]. But when we analyzed it in detail during the pro-
gression of the disease, the CB1 activation was greater
during AD stages I-II, decreased to levels similar to
the control group during AD stages III-IV, and con-
tinued to fall below control group levels during AD
stages V-VI. These effects were significant at the pyra-
midal layers and the dentate gyrus, areas in which
the cannabinoid receptors are more densely located at
synaptic terminals. Therefore, the increase of activity
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Table 2
Autoradiographic densities for the specific binding of [3H]CP55,940 in the human brain samples from control and AD patients (fmol/mg)
Brain area Controls AD I-II AD III-IV AD V-VI
Frontal cortex (n = 9) (n = 9–10) (n = 6)
Layer I-III 57.8 ± 13.9 56.2 ± 7.8 67.1 ± 12.8 –
Layer IV 59.7 ± 16.4 51.1 ± 5.4 69.4 ± 10.9 –
Layer V 54.6 ± 13.1 60.4 ± 7.8 64.9 ± 8.6 –
Layer VI 50.4 ± 9.8 68.5 ± 6.1 91.2 ± 8.6∗,b –
Hippocampus
CA1 (n = 4–6) (n = 4–7) (n = 5) (n = 4–5)
Lacunosum moleculare 40.6 ± 5.1 48.4 ± 6.5 51.4 ± 8.4 42.8 ± 3.2
Oriens 40.6 ± 8 42.2 ± 3.1 39.3 ± 4.6 43.9 ± 5.4
Pyramidal 64.6 ± 9.6 84.1 ± 10 87.5 ± 15.9 48.1 ± 2.1∗,d
Radiatum 42.5 ± 5.9 46.8 ± 5.7 55.7 ± 9.6 44.4 ± 4.9
CA3 (n = 6–7) (n = 7–8) (n = 6) (n = 7)
Lacunosum moleculare 44.2 ± 6.7 53.9 ± 5.2 65.8 ± 5.5 40.5 ± 3.3∗,d
Oriens 42.6 ± 5.1 42.2 ± 3.7 51.9 ± 7.6 44.5 ± 4.7
Pyramidal 68.3 ± 7.3 88.4 ± 6.2 98.3 ± 9.6 58.1 ± 3.5∗,c,d
Radiatum 41.6 ± 5.0 47.0 ± 8.9 59.6 ± 6.2∗,b 44.9 ± 4.5
Dentate gyrus (n = 4–6) (n = 6) (n = 7) (n = 4–5)
Granular 80.2 ± 10.1 95.8 ± 3.5 99.5 ± 8.5 70.8 ± 8.5∗,c
Hilus 64.3 ± 9.9 67.7 ± 6.3 74.6 ± 6.6 65.2 ± 5.6
Subiculum (n = 5–7) (n = 6–7) (n = 5–6) (n = 6)
Lacunosum moleculare 44.6 ± 6.5 46.4 ± 7.5 64.8 ± 7.1 36.7 ± 1.2∗,d
Oriens 45.5 ± 6.3 38.3 ± 4.6 55.9 ± 6.3 42.4 ± 2.7
Pyramidal 59.4 ± 6.5 101.1 ± 2.7∗,a 107.3 ± 13.7 49.1 ± 4.2∗,d
Radiatum 44.8 ± 6.2 59.3 ± 8.6 72.4 ± 5.6 36.3 ± 1.1∗,d
Entorhinal cortex (n = 4) (n = 3) (n = 3) (n = 3)
Layer I 71.3 ± 17 55.1 ± 15.8 60.9 ± 0.6 58.7 ± 14.9
Layer II-III 53.0 ± 10.8 73.2 ± 5.9 94.5 ± 3.9∗,b 67.8 ± 22.1∗,d
Layer IV-VI 48.5 ± 9.1 63.5 ± 9.5 70.0 ± 3.2 60.5 ± 14∗,d
Amygdala (n = 3–4) (n = 6–9) (n = 4–5)
Lateral nucleus 7.1 ± 1.9 5.3 ± 0.9 4.3 ± 0.9 –
Basal nucleus (magnocellular) 3.9 ± 0.5 4.5 ± 0.4 3.5 ± 0.8 –
Basal forebrain (n = 4) (n = 6) (n = 4)
Nucleus basalis (Meynert) 47.1 ± 4.7 40.1 ± 0.9 41.5 ± 8.0 –
Striatum (n = 5) (n = 12) (n = 8) (n = 5)
Caudate-putamen 62.7 ± 8.6 94.7 ± 4.8∗a 75.4 ± 6.9 66.4 ± 4.5∗,c
Data are mean ± SEM values. (n): number of cases used. (–): less than 3 samples available. The p values were calculated by the Kruskal-Wallis
non-parametric test followed by Dunn’s test. aAD I-II versus control, bAD III-IV versus control, cAD I-II versus AD V-VI, dAD III-IV versus
AD V-VI. ∗p < 0.05.
during AD stages I-II might be an initial response to
neural impairment.
Moreover, an increase of monoacylglycerol lipase
activity has been described in AD stages V-VI
that might contribute to the accumulation of 2-
arachidonoyl glycerol, resulting in synaptic failure
with the consequent downregulation of CB1 recep-
tors [22]. However, immunohistochemical assays have
described no changes in CB1 receptors [23].
We observed that the regulation on CB1 densities
was delayed during the advance of AD compared with
the modulation of CB1 activity. The [3H]CP55,940
binding sites were decreased at later stages in the pyra-
midal layers of different hippocampal areas and the
inner layers of the entorhinal cortex.
The nbM cholinergic cells innervate the amygdala,
where the functional CB1 receptors decreased in the
lateral nucleus of the amygdala in AD patients. In
contrast, the number and expression of cannabinoid
receptors in the human amygdala are low [24, 7].
We also observed low CB1 receptor density in the
amygdala, which was conserved in AD patients. This
finding suggests that the down-regulation of cannabi-
noid activity is not indicating modulation in receptor
density. On the contrary, CB1 activity in the striatal
area was conserved in AD patients, but CB1 density
was high and was increased at the initial AD stages,
continuing to a reduction with the progression of the
disease, which might be caused by the loss of affer-
ents from areas such as the globus pallidus and the
substantia nigra, where a reduction of CB1 of recep-
tors had been reported [7]. Although the incidence
of co-morbidity with parkinsonism is frequent in AD
patients, we were unaware if this was the case in any
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of the cases included in the present study. In addition,
maintained levels of CB1 cannabinoid receptors have
been described in Parkinson’s disease [25].
In summary, CB1 receptors were more efficient in
the patients at the earlier AD stages, specifically in hip-
pocampal areas. These regulations on CB1 signaling
might precede to the accumulation of the neuropatho-
logical markers of the AD in specific brain areas. On
the contrary, at the most advanced stages of AD, CB1
efficacy diminished in both the hippocampus and the
frontal cortex. The modulation of CB1 density follows
the same pattern, but occurs later in the course of AD.
The initial hyperactivity of the endocannabinoid sys-
tem accounts for the possible compensation of synaptic
impairment; however, the intimate and unknown cause
of AD continues with neurodegeneration and deter-
mines a loss of CB1 synapses. CB1 stimulation might
have therapeutic relevance during the initial and mod-
erate stages of AD.
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